MTND4LP11

Across TCGA pan-cancer cohorts, MTND4LP11 RNA is linked to patient survival in 5 of 34 cancer types, making it the most broadly survival-associated MTND4LP11 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher MTND4LP11 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MTND4LP11 expression acts as an unfavorable survival marker.

LIHC, SKCM, and DLBC are the cancer types where MTND4LP11 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Tertile	II,III,IV	0.076	0.431	<.001	81	view →
SKCM	OS	Tertile	All	0.080	0.392	.009	63	view →
DLBC	OS	Tertile	III,IV	0.175	0.874	.025	27	view →
KIRC	DFS	Tertile	All	0.204	0.633	.006	18	view →
KIRP	OS	Tertile	All	0.786	0.950	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MTND4LP11–LIHC (DFS)

Open the LIHC breakdown →